Diabetic Nephropathy Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

The global Diabetic Nephropathy market is on track for significant growth over the next decade, with recent market analysis indicating a compound annual growth rate (CAGR) of 4.7%. By 2031, the market is expected to reach a valuation of approximately $3.6 billion. In 2024, the market is projected to achieve a revenue of $2.6 billion, underscoring a steady upward trajectory driven by advancements in research and development and the rising prevalence of diabetes.

Historical Sales Analysis and Future Market Outlook

From 2017 to 2022, the global Diabetic Nephropathy market experienced a significant period of growth. This positive trend is anticipated to continue as the market expands, driven by the increasing incidence of both type 1 and type 2 diabetes. Diabetic nephropathy, also known as diabetic kidney disease, poses a substantial challenge to kidney function, emphasizing the need for effective treatments and management strategies.

Key Drivers of Market Growth

Several factors contribute to the growth of the Diabetic Nephropathy market:

1. Increasing Prevalence of Diabetes: The rising number of diabetic patients globally is a primary driver. According to the International Diabetes Federation, diabetes affected 537 million people in 2021, with projections estimating this number will reach 643 million by 2030.

2. Advancements in Research and Development: Ongoing research efforts are pivotal in developing new treatments. ClinicalTrials.gov reported over 50 ongoing studies related to diabetic nephropathy treatment in 2021, underscoring the focus on this area.

3. Introduction of New Medications: The approval of new drugs, such as the FDA-approved SGLT2 inhibitor canagliflozin (Invokana) in 2019, is enhancing treatment options and outcomes for diabetic nephropathy patients.

4. Increased Awareness and Diagnostic Rates: Enhanced awareness and diagnostic rates of chronic kidney disease (CKD) and diabetic nephropathy are driving market growth, especially in developed countries like the United States.

Challenges Impacting Market Growth

Despite the positive outlook, the Diabetic Nephropathy market faces several challenges:

1. High Cost of Treatment: The financial burden associated with diabetic nephropathy treatment is significant. Patients with diabetic kidney disease (DKD) incur higher medical costs compared to those without complications.

2. Lack of Comprehensive Treatment: Currently, no complete cure exists for diabetic nephropathy. Available medications primarily aim to control or delay disease progression.

3. Inadequate Healthcare Infrastructure: In low-income countries, inadequate planning for diabetic nephropathy treatment and a lack of trained specialists hinder market growth.

Regional Market Insights

1. United States: Accounting for approximately 33.7% of the global market share, the United States remains a dominant player. The high prevalence of chronic kidney disease (CKD) and well-established healthcare infrastructure contribute to the country's market strength.

2. United Kingdom: With a 5.4% market share, the UK benefits from developed guidelines for diabetic nephropathy treatment, emphasizing individualized care and accurate blood pressure management.

3. Germany: Holding about 6.4% of the market, Germany shows significant potential due to high rates of undiagnosed early CKD and an increasing focus on early diagnosis and tailored treatments.

4. China: With a 4.2% market share, China is expected to see growth driven by government initiatives like the Healthy China Initiative (2019-2030), aimed at raising awareness and improving diabetes management.

Category-wise Market Insights

1. Drug Class: Angiotensin receptor blockers (ARBs) accounted for 42.3% of the total market share. These medications are effective in slowing the progression of diabetic nephropathy and reducing proteinuria in type 2 diabetes patients.

2. Diabetes Type: Type-II diabetes, which constituted around 76.5% of the market share, is a major focus area due to its high prevalence and association with end-stage kidney disease (ESKD).

3. Route of Administration: The oral route of administration held about 62.3% of the market share, favored for its non-invasiveness, patient compliance, and convenience.

4. Distribution Channel: Hospital pharmacies dominated the market with a 63.1% share, driven by the growing number of hospital visits for diagnosis and treatment of diabetic nephropathy.

Competitive Landscape

Key players in the Diabetic Nephropathy market are investing heavily in research and development to introduce innovative treatments. Strategic alliances, mergers, and acquisitions are common as companies aim to expand their market presence. Notable developments include:

The joint announcement by Boehringer Ingelheim and Eli Lilly and Company regarding the FDA approval of empagliflozin (Jardiance) tablets in January 2023 for reducing cardiovascular death and kidney disease progression in CKD patients.
Bayer's introduction of finerenone in India in August 2022 as a treatment for type-2 diabetes and chronic kidney disease (CKD).

The global Diabetic Nephropathy market's robust growth outlook highlights the increasing need for effective treatments and strategic initiatives to address this critical healthcare challenge. As the market evolves, continued advancements in research and development, coupled with heightened awareness and diagnostic efforts, will be pivotal in shaping the future landscape of diabetic nephropathy treatment.

Key Market Players Include

AstraZeneca (UK.)
Pfizer Inc (US.)
Allergan, Inc (Ireland)
Bristol-Myers Squibb Company (US.)
Endo International plc (Ireland)
Dr. Reddy's Laboratories Ltd (India)
Sun Pharmaceutical Industries Ltd (India)
Teva Pharmaceutical Industries Ltd (Israel)
Novartis AG (Switzerland)
Eli Lilly and Company (India)
Mylan NV (US.)
Cipla Inc (India)
Lupin (India)
Aurobindo Pharma (India)
Sanofi (France)
Fresenius SE & Co. KGaA (Germany)
F. Hoffmann-La Roche Ltd (Switzerland)
Takeda Pharmaceutical Company Limited (Japan)
Abbott (US.)

Global Diabetic Nephropathy market is Segmented as Below:

By Drug Class:

Diuretics
Angiotensin Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
Others

By Diabetes Type:

Type-1 Diabetes
Type-2 Diabetes

By Route of Administration:

Oral
Parenteral
Others

By Distribution Channel:

Hospitals Pharmacies
Retail Pharmacies
Online Pharmacies
Others

By Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East and Africa

1. Executive Summary

1.1. Global Diabetic Nephropathy Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Diabetic Nephropathy Market Outlook, 2018 - 2031

3.1. Global Diabetic Nephropathy Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Diuretics
  - 3.1.1.2. Angiotensin Receptor Blockers
  - 3.1.1.3. Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
  - 3.1.1.4. Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
  - 3.1.1.5. Others
3.2. Global Diabetic Nephropathy Market Outlook, by Diabetes Type, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Type-1 Diabetes
  - 3.2.1.2. Type-2 Diabetes
3.3. Global Diabetic Nephropathy Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Oral
  - 3.3.1.2. Parenteral
  - 3.3.1.3. Others
3.4. Global Diabetic Nephropathy Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. North America
  - 3.4.1.2. Europe
  - 3.4.1.3. Asia Pacific
  - 3.4.1.4. Latin America
  - 3.4.1.5. Middle East & Africa

4. North America Diabetic Nephropathy Market Outlook, 2018 - 2031

4.1. North America Diabetic Nephropathy Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Diuretics
  - 4.1.1.2. Angiotensin Receptor Blockers
  - 4.1.1.3. Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
  - 4.1.1.4. Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
  - 4.1.1.5. Others
4.2. North America Diabetic Nephropathy Market Outlook, by Diabetes Type, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Type-1 Diabetes
  - 4.2.1.2. Type-2 Diabetes
4.3. North America Diabetic Nephropathy Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Oral
  - 4.3.1.2. Parenteral
  - 4.3.1.3. Others
- 4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Diabetic Nephropathy Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. U.S. Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 4.4.1.2. U.S. Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 4.4.1.3. U.S. Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 4.4.1.4. Canada Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 4.4.1.5. Canada Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 4.4.1.6. Canada Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
- 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Diabetic Nephropathy Market Outlook, 2018 - 2031

5.1. Europe Diabetic Nephropathy Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Diuretics
  - 5.1.1.2. Angiotensin Receptor Blockers
  - 5.1.1.3. Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
  - 5.1.1.4. Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
  - 5.1.1.5. Others
5.2. Europe Diabetic Nephropathy Market Outlook, by Diabetes Type, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Type-1 Diabetes
  - 5.2.1.2. Type-2 Diabetes
5.3. Europe Diabetic Nephropathy Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Oral
  - 5.3.1.2. Parenteral
  - 5.3.1.3. Others
- 5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Diabetic Nephropathy Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Germany Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.2. Germany Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.3. Germany Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 5.4.1.4. U.K. Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.5. U.K. Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.6. U.K. Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 5.4.1.7. France Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.8. France Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.9. France Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 5.4.1.10. Italy Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.11. Italy Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.12. Italy Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 5.4.1.13. Turkey Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.14. Turkey Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.15. Turkey Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 5.4.1.16. Russia Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.17. Russia Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.18. Russia Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 5.4.1.19. Rest of Europe Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 5.4.1.20. Rest of Europe Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.21. Rest of Europe Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
- 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Diabetic Nephropathy Market Outlook, 2018 - 2031

6.1. Asia Pacific Diabetic Nephropathy Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Diuretics
  - 6.1.1.2. Angiotensin Receptor Blockers
  - 6.1.1.3. Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
  - 6.1.1.4. Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
  - 6.1.1.5. Others
6.2. Asia Pacific Diabetic Nephropathy Market Outlook, by Diabetes Type, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Type-1 Diabetes
  - 6.2.1.2. Type-2 Diabetes
6.3. Asia Pacific Diabetic Nephropathy Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Oral
  - 6.3.1.2. Parenteral
  - 6.3.1.3. Others
- 6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Diabetic Nephropathy Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. China Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.4.1.2. China Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.3. China Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 6.4.1.4. Japan Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.4.1.5. Japan Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.6. Japan Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 6.4.1.7. South Korea Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.4.1.8. South Korea Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.9. South Korea Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 6.4.1.10. India Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.4.1.11. India Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.12. India Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 6.4.1.13. Southeast Asia Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.4.1.14. Southeast Asia Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.15. Southeast Asia Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 6.4.1.16. Rest of Asia Pacific Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 6.4.1.17. Rest of Asia Pacific Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.18. Rest of Asia Pacific Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
- 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Diabetic Nephropathy Market Outlook, 2018 - 2031

7.1. Latin America Diabetic Nephropathy Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Diuretics
  - 7.1.1.2. Angiotensin Receptor Blockers
  - 7.1.1.3. Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
  - 7.1.1.4. Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
  - 7.1.1.5. Others
7.2. Latin America Diabetic Nephropathy Market Outlook, by Diabetes Type, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Type-1 Diabetes
  - 7.2.1.2. Type-2 Diabetes
7.3. Latin America Diabetic Nephropathy Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Oral
  - 7.3.1.2. Parenteral
  - 7.3.1.3. Others
- 7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Diabetic Nephropathy Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Brazil Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.4.1.2. Brazil Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 7.4.1.3. Brazil Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 7.4.1.4. Mexico Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.4.1.5. Mexico Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 7.4.1.6. Mexico Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 7.4.1.7. Argentina Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.4.1.8. Argentina Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 7.4.1.9. Argentina Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 7.4.1.10. Rest of Latin America Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 7.4.1.11. Rest of Latin America Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 7.4.1.12. Rest of Latin America Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
- 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Diabetic Nephropathy Market Outlook, 2018 - 2031

8.1. Middle East & Africa Diabetic Nephropathy Market Outlook, by Drug Class, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Diuretics
  - 8.1.1.2. Angiotensin Receptor Blockers
  - 8.1.1.3. Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
  - 8.1.1.4. Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
  - 8.1.1.5. Others
8.2. Middle East & Africa Diabetic Nephropathy Market Outlook, by Diabetes Type, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Type-1 Diabetes
  - 8.2.1.2. Type-2 Diabetes
8.3. Middle East & Africa Diabetic Nephropathy Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Oral
  - 8.3.1.2. Parenteral
  - 8.3.1.3. Others
- 8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Diabetic Nephropathy Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. GCC Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.4.1.2. GCC Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.3. GCC Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 8.4.1.4. South Africa Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.4.1.5. South Africa Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.6. South Africa Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 8.4.1.7. Egypt Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.4.1.8. Egypt Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.9. Egypt Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 8.4.1.10. Nigeria Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.4.1.11. Nigeria Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.12. Nigeria Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
  - 8.4.1.13. Rest of Middle East & Africa Diabetic Nephropathy Market by Drug Class, Value (US$ Bn), 2018 - 2031
  - 8.4.1.14. Rest of Middle East & Africa Diabetic Nephropathy Market by Diabetes Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.15. Rest of Middle East & Africa Diabetic Nephropathy Market by Route of Administration, Value (US$ Bn), 2018 - 2031
- 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By Route of Administration vs by Diabetes Type Heat map
9.2. Company Market Share Analysis, 2022
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. AstraZeneca
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Pfizer Inc.
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. Allergan, Inc.
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. Bristol-Myers Squibb Company
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. Endo International plc
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Dr. Reddy's Laboratories Ltd
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Sun Pharmaceutical Industries Ltd
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Teva Pharmaceutical Industries Ltd
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Novartis AG
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. Eli Lilly and Company
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development
- 9.4.11. Mylan NV
  - 9.4.11.1. Company Overview
  - 9.4.11.2. Product Portfolio
  - 9.4.11.3. Financial Overview
  - 9.4.11.4. Business Strategies and Development

10. Appendix

10.1.Research Methodology
10.2.Report Assumptions
10.3.Acronyms and Abbreviations